Assessment of Abuse Potential of Rapastinel in Humans
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - 55 |
Updated: | 4/3/2019 |
Start Date: | November 1, 2018 |
End Date: | March 29, 2019 |
A Single-center, Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate
the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR
antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational
polydrug users.
the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR
antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational
polydrug users.
Inclusion Criteria:
- Participant must be a current recreational polydrug user
- Have a supine systolic blood pressure (BP) ≥ 95 mm Hg and ≤ 145 mg Hg, or sitting
diastolic BP ≥ 50 mm Hg and ≤ 90 mm Hg at the Screening Visit.
- Have negative test results for benzoylecgonine (cocaine), methadone, barbiturates,
amphetamines, benzodiazepines, alcohol, oxycodone and other opioids, and phencyclidine
at any admission
- Able, as assessed by the investigator, and willing to follow study instructions and
likely to complete all required study visits
Exclusion Criteria:
- Evidence of drug or alcohol dependence (excluding nicotine and caffeine) within the
past 2 years
- Suicidal risk based on the opinion of the principal investigator (or appropriately
trained designee)
- History of violent or psychotic behavior when taking psychedelic drugs, or unwilling
to take a drug that might alter perception in a controlled setting
- Have taken or require concomitant treatment with any CNS depressants, or cannot safely
discontinue these medications within 14 days (or 5 half-lives, whichever is longer)
before study treatment administration
- Previously participated in an investigational study of rapastinel.
- Participation in any other clinical investigation using an experimental drug within 30
days, 5 half-lives or twice the duration of the biological effect of the study
treatment (whichever is longer), prior to study treatment administration or is
concurrently enrolled in any clinical trial, judged not to be scientifically or
medically compatible with this study
- Consumption of alcohol within 72 hours before administration of study treatment
- Breastfeeding
- Unable to refrain from consuming caffeine or xanthine-containing compounds such as
tea, coffee, soft drinks, energy sports drinks or chocolate (more than 48 oz/day) from
48 hours before administration of study treatment.
- Have consumed dietary supplements or other foods or beverages that may affect various
drug metabolizing enzymes and transporters (eg, grapefruit, grapefruit juice,
grapefruit-containing beverages), vegetables from the mustard green family (eg, kale,
broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and
charbroiled meats within 14 days prior to dosing or unable to refrain from consumption
during the study.
- The ability to tolerate IV ketamine as judged by the Investigator, based on available
safety data, as well as pharmacodynamic data.
We found this trial at
1
site
Click here to add this to my saved trials